Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Other Accumulated Expenses (2018 - 2025)

10x Genomics' Other Accumulated Expenses history spans 8 years, with the latest figure at $10.9 million for Q4 2025.

  • For Q4 2025, Other Accumulated Expenses changed N/A year-over-year to $10.9 million; the TTM value through Dec 2025 reached $10.9 million, changed N/A, while the annual FY2025 figure was $10.9 million, N/A changed from the prior year.
  • Other Accumulated Expenses for Q4 2025 was $10.9 million at 10x Genomics, down from $12.4 million in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $44.8 million in Q1 2021 and bottomed at $2.8 million in Q3 2021.
  • The 5-year median for Other Accumulated Expenses is $6.3 million (2022), against an average of $10.2 million.
  • The largest YoY upside for Other Accumulated Expenses was 151.08% in 2022 against a maximum downside of 85.92% in 2022.
  • A 5-year view of Other Accumulated Expenses shows it stood at $8.3 million in 2021, then decreased by 19.05% to $6.7 million in 2022, then crashed by 34.2% to $4.4 million in 2023, then rose by 29.59% to $5.7 million in 2024, then soared by 90.09% to $10.9 million in 2025.
  • Per Business Quant, the three most recent readings for TXG's Other Accumulated Expenses are $10.9 million (Q4 2025), $12.4 million (Q3 2025), and $12.8 million (Q2 2025).